Dipeptidyl Peptidase 4 Inhibitor

DRUG3 trials

Sponsors

Changhua Christian Hospital, Mayo Clinic, Attikon Hospital

Conditions

Cardiac DiseaseDiabetes Type 2ProteinuriaType 2 DiabetesType 2 Diabetes Mellitus

Phase 4

Comparing the Renal Effect of Dipeptidyl-peptidase 4 Inhibitors and Sulfonylureas

CompletedNCT03983551

Changhua Christian HospitalProteinuria, Type 2 Diabetes Mellitus

Start: 2016-03-01End: 2018-02-28Updated: 2019-06-14

Unknown Phase

Second-line Therapies for Patients With Type 2 Diabetes and Moderate Cardiovascular Disease Risk

CompletedNCT05214573

Mayo ClinicCardiac Disease, Type 2 Diabetes

Start: 2021-12-01End: 2025-07-22Updated: 2025-10-10

The Effect of Semaglutide on Cardiovascular Markers and Liver Function

RecruitingNCT06301191

Attikon HospitalDiabetes Type 2

Start: 2022-03-01End: 2024-05-01Target: 50Updated: 2024-03-08

Related Papers

Kidney Outcomes with Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas in Type 2 Diabetes and Moderate Cardiovascular Risk

Clinical Journal of the American Society of Nephrology2024-10-084 citations

Effectiveness of glucose-lowering medications on cardiovascular outcomes in patients with type 2 diabetes at moderate cardiovascular risk.

2024-04-0310 citations